Next Science Limited Stock

Equities

NXS

AU0000041329

Pharmaceuticals

Market Closed - Australian S.E. 02:10:46 2024-05-10 am EDT 5-day change 1st Jan Change
0.38 AUD -2.56% Intraday chart for Next Science Limited +15.15% +11.76%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 32.71M 49.55M Sales 2025 * 40.67M 61.61M Capitalization 73.19M 111M
Net income 2024 * -13M -19.69M Net income 2025 * -8M -12.12M EV / Sales 2024 * 1.85 x
Net cash position 2024 * 12.75M 19.32M Net cash position 2025 * 5.02M 7.6M EV / Sales 2025 * 1.68 x
P/E ratio 2024 *
-5.14 x
P/E ratio 2025 *
-12.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.65%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Next Science Limited

1 day-2.56%
1 week+15.15%
Current month+22.58%
1 month+11.76%
3 months+13.43%
6 months+28.81%
Current year+11.76%
More quotes
1 week
0.32
Extreme 0.32
0.39
1 month
0.31
Extreme 0.31
0.50
Current year
0.29
Extreme 0.285
0.50
1 year
0.18
Extreme 0.18
0.67
3 years
0.18
Extreme 0.18
1.98
5 years
0.18
Extreme 0.18
4.73
10 years
0.18
Extreme 0.18
4.73
More quotes
Managers TitleAgeSince
Founder - 17-10-19
Chief Executive Officer - 23-07-09
Director of Finance/CFO - 23-05-25
Members of the board TitleAgeSince
Chief Executive Officer - 23-07-09
Director/Board Member - 23-08-22
Chairman 62 18-09-30
More insiders
Date Price Change Volume
24-05-10 0.38 -2.56% 108,674
24-05-09 0.39 +11.43% 22,341
24-05-08 0.35 -2.78% 92,299
24-05-07 0.36 +2.86% 103,895
24-05-06 0.35 +6.06% 212,504

Delayed Quote Australian S.E., May 10, 2024 at 02:10 am EDT

More quotes
Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.2509 USD
Average target price
0.2415 USD
Spread / Average Target
-3.75%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW